Women & Addictions
in the European Union
A comprehensive evidence review across prevalence, the gender gap, access barriers, existing responses and institutional frameworks — covering all 27 EU member states and the United Kingdom.
The scale of the problem in Europe
Europe holds the world's highest alcohol consumption per capita. Eight of the ten countries with the greatest per-capita intake belong to the WHO European Region.
Substance use patterns
- Cannabis remains the most widely used illicit drug. Among 15–16 year-olds (ESPAD 2024, 37 countries), 14% report lifetime use.
- Gender convergence — differences narrow significantly in younger generations, signalling an emerging prevalence shift.
- Telescope effect — women progress from first use to dependence significantly faster than men, across most substance categories.
- Alcohol causal link — alcohol is responsible for almost 1 in 11 deaths in the European region and is causally linked to more than 200 diseases.
Sources: EUDA Statistical Bulletin 2025 · ESPAD 2024 · WHO/EU Alcohol Fact Sheet Oct. 2024 · The Lancet Regional Health – Europe 2024
Why this matters for AI-assisted support
- The sheer scale of unmet need creates a structural gap that digital, low-threshold tools are uniquely positioned to address.
- Women's faster progression toward dependence argues for earlier, more accessible intervention — before clinical thresholds are reached.
- Anonymous conversational AI offers a first-contact channel that carries none of the stigma barriers attached to formal services.
- The ANBORELA system is designed precisely for this pre-clinical, high-need population.
ANBORELA analysis based on EUDA 2025–2026 evidence base
The invisible problem: who uses vs who receives help
Women represent 25% of serious drug cases across Europe, yet account for only 20% of those entering specialised treatment. The gap is not in consumption — it is in access.
Who uses — and who gets treated
Sources: EUDA Gender and drugs FAQ (March 2026) · EUDA Women and drugs mini-guide · EUDA International Women's Day 2019
A different map for women
Women present distinct profiles across non-substance addictions — often with faster progression, later onset, and higher psychiatric comorbidity than men in the same category.
| Addiction type | Men (prevalence) | Women (prevalence) | Specific pattern in women | Source |
|---|---|---|---|---|
| Gambling disorder (Europe) | 4.5% | 2.9% | Faster progression; later onset; higher psychiatric comorbidity. Prefer lottery-style over skill games. | Lancet 2024 |
| Gambling disorder (global) | 54.7M cases | 25.3M cases | Prefer games of chance (lottery) over games of skill. Heavily under-represented in help-seeking. | Lancet 2024 |
| Gaming disorder (adolescents) | 6.8% | 1.3% | Sexual minority women: OR ×2.3 elevated risk. Low detection in services due to gender assumptions. | ESPAD 2024 |
| Internet / shopping addiction | Lower risk | Higher risk | Used as coping mechanism; linked to gender roles and social isolation. Under-pathologised clinically. | Pompidou 2024 |
Sources: The Lancet 2024 · ESPAD 2024 · Council of Europe Pompidou Group 2024 · PMC/Frontiers Behavioural Addiction 2022–2023
Why women do not seek help: 8 documented structural barriers
These are not individual failures. They are systemic, structural, and reinforcing. Each one alone is enough to prevent help-seeking; in combination, they are insurmountable without targeted intervention.
Sources: EUDA FAQ Gender and Drugs 2026 · European Parliament Gender Inequalities in Medical Research 2025 · EUDA mini-guide Women and Drugs
What exists today: documented programmes across the EU
Several evidence-based models have demonstrated effectiveness for women. Coverage, however, remains deeply unequal across member states — and digital, low-threshold options are systematically underdeveloped.
Women-only services
Delivered by women, for women — with integrated attention to trauma, gender-based violence, maternity and mental health. Identified by EUDA as the most effective response for women with a history of intimate partner violence.
- Coverage remains very uneven between countries
- Demand consistently outstrips availability
- Models from Ireland and the Netherlands cited as leading practice
Integrated perinatal programmes
Simultaneous treatment of addiction and pregnancy or new motherhood — including prenatal care, parenting education, and accommodation that allows children to remain with their mothers during treatment.
- Portugal (ICAD), Ireland (HRB) and the Netherlands cited as leaders
- Directly addresses the custody barrier
- High retention rates compared to standard services
Trauma-informed care
The European standard recommended by EUDA and the Pompidou Group. Requires safe, non-judgemental environments with gender perspective and systematic coordination with gender-based violence services.
- Recommended across all 27 EU member states
- Implementation highly variable in practice
- Requires sustained professional training investment
Anonymous & digital access
Anonymous peer groups (AA, NA), helplines, and online/hybrid care. Critical for women who do not present in person. Prioritised by the Pompidou Group and EUDA for 'invisible' populations — yet systematically under-evaluated.
- No EU-wide effectiveness evaluation currently exists
- Demand signals far exceed current supply
- ANBORELA is designed to operate within this evidence gap
Detection in adjacent systems
Women reach services through mental health, gynaecology or emergency routes — where addiction is rarely identified. Training primary care staff in gender-sensitive detection is a stated EU Action Plan priority.
- Low implementation rate across primary care networks
- Structural disconnect between addiction and mental health services
- AI-assisted screening tools represent an emerging opportunity
What we know — and what is still missing
The ANBORELA evidence base draws exclusively on peer-reviewed publications, EU agency primary data, and international health organisation reports. Critical research gaps define the frontier where ANBORELA aims to contribute.
Evidence base
- EUDA — Gender and Drugs FAQ (March 2026)
- EUDA — European Drug Report 2025
- EUDA — ESPAD 2024 (adolescents, 37 countries)
- WHO/Europe — Alcohol Fact Sheet (October 2024)
- The Lancet — Gambling disorder global (2024)
- Brain Sciences — Gender perspective dual diagnosis (2021)
- European Psychiatry — AUD in women (August 2025)
- Council of Europe — Online gambling risks (2024)
- European Parliament — Gender inequalities in medical research (2025)
- Pompidou Group — Behavioural addictions & women (2024)
Where evidence is missing
Who regulates, coordinates and funds in the EU
Understanding the regulatory landscape is critical for any research partnership. ANBORELA has been designed from inception to operate within — and contribute to — this institutional architecture.
European institutions
- EUDA — European technical regulator for drugs policy
- Reitox Network — 27 national focal points
- European Commission + Council of the EU (policy)
- Pompidou Group — Council of Europe
- WHO Europe · Eurocare · EUREC (ethics)
Member state bodies
- Ministry or national agency (Reitox focal point)
- National or university/hospital ethics committee
- Country-specific NGOs and low-threshold networks
- Anonymous peer groups (AA, NA) — active European network
Designed for this ecosystem
- Anonymous and digital access — no barriers to entry
- Trauma-informed, non-punitive design by default
- No threat to maternity — custody-neutral architecture
- Coordination-ready with mental health & GBV services
- Low-threshold: no appointment, no name, no cost
- Pre-deployment ethics review before any public access
The evidence in four figures
Is your institution ready to co-design the evidence?
We invite European universities, public health institutes and research bodies to join the ANBORELA scientific steering group. Ethics-first, GDPR-compliant, Big-Tech-independent. Open to EU and UK partners.